In this episode of Px Pulse, Ntando Yola, a veteran advocate and part of the Coalition to Accelerate and Support Prevention Research (CASPR) shares his advocacy priorities for R4P and beyond. But first, AVAC’s Emily Bass talks about the just-launched 2018 annual report from AVAC, this year titled No Prevention, No End!
AVAC Report 2018 & HIV R4P
Combination Prevention and AIDS 2018
In this episode, featuring Ambassador Deborah Birx, we take a look at one area of great importance that was center stage at the AIDS 2018 conference in Amsterdam: primary prevention.
Cure Research and Analytic Treatment Interruption
In this episode of Px Pulse, researchers and advocates debate the rationale, risks and ethics of interrupting treatment as part of cure research. This is known as analytic treatment interruption or ATI.
Oral PrEP Enrollment Snapshot
For trends in oral PrEP uptake, check out the Oral PrEP Enrollment Snapshot. This PowerPoint deck illustrates major findings from the tracker with heat maps showing where people are initiating PrEP, updates against targets and more. A PDF version is also available.
Global Investment in HIV Cure Research and Development in 2017
In 2014, the HIV Vaccines and Microbicides Resource Tracking Working Group and AVAC began a collaboration with the International AIDS Society’s (IAS) Towards an HIV Cure initiative to review and allocate grants towards HIV cure research and analyze data on global funding. The working group released a report in July 2018, Global Investment in HIV Cure Research and Development in 2017: After Years of Rapid Growth Funding Increases Slow.
PrEP Initiations by Country in Africa
AVAC tracks global PrEP use by conducting quarterly surveys of ongoing oral PrEP demonstration and implementation projects, and collecting data from manufacturers and government agencies. This graphic shows data on PrEP initiations in Africa. For more trends in oral PrEP uptake, check out the Oral PrEP Enrollment Snapshot slide deck and visit PrEPWatch.
A Global Look at PrEP Introduction
The introduction of PrEP took many years to reach current levels of acceptance and availability. The next phase of distribution is on track to move faster. This is an updated version of a graphic appearing in AVAC Report 2017: Mixed messages and how to untangle them.
HIV Vaccine Science, Research, Updates and Advocacy
With HIV Vaccine Awareness Day (HVAD) in the spotlight earlier this month, AVAC’s May episode of PxPulse features four experts steeped in HIV vaccine research. Together they help set expectations for where the field is now and where it is going.
Vaccines Efficacy Trials: A surge of activity
A picture of the status of vaccine trials since 2003: The four trials shown here represent an unprecedented number of late phase trials underway in vaccines research.
Prevention Research & Oral PrEP Rollout: The evolving context for HIV prevention research
Many of the current or planned prevention trials are taking place in countries where daily oral PrEP is available or will be soon. This infographic shows the status PrEP and the location of scheduled trials by country.